Drug intelligence / Profile preview

harmine

Development stage
Phase 1
Modality
Small Molecules
Administration
Oral
01

Overview

Harmine is a naturally occurring β-carboline alkaloid found in several plants, notably *Peganum harmala* (Syrian rue) and *Banisteriopsis caapi*, the latter being a key ingredient in the psychoactive brew ayahuasca. Chemically, it is known as 7-methoxy‑1‑methyl‑β‑carboline. Harmine acts primarily as a reversible inhibitor of monoamine oxidase A (MAO-A), thereby increasing levels of monoamine neurotransmitters such as serotonin, norepinephrine, and dopamine[2][1]. It also inhibits dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) and related kinases[8][1]. Harmine has been studied for its hallucinogenic properties at higher doses and has shown various pharmacological activities including anti-tumor, antimicrobial, antiplasmodial, antioxidant, neuroprotective effects, and potential antidepressant activity[5][9]. Historically investigated for Parkinson’s disease treatment in the early to mid 20th century[2], it remains an investigational compound with no current regulatory approval for medical use.

Other names
banisterinetelepathineleucoharmineyageineyajeine
02

Targets

DYRK2 (Dual-specificity tyrosine-phosphorylation-regulated kinase 2)DYRK1A (Dual-specificity tyrosine-phosphorylation-regulated kinase 1A)MAOA (Monoamine oxidase A)

Beyond the preview

Go deeper on harmine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on harmine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call